>Mercado global de amaurose congénita de Leber, por tipo de doença (tipo infantil, tipo juvenil e outros), tipo (terapêutica e diagnóstico), utilizador final (hospitais, clínicas especializadas, centros de cirurgia ambulatória, cuidados de saúde domiciliários e outros), canal de distribuição (concurso direto e Vendas a retalho) Tendências e previsões do setor para 2029.
Análise e insights de mercado
O mercado global de amaurose congénita leber é impulsionado por fatores como o aumento da prevalência de doenças crónicas, como a diabetes e as doenças gastrointestinais, um número crescente de futuros players e a popularidade das bombas de infusão nos serviços de apoio domiciliário, que melhoram a sua procura, para além de aumentar o investimento em investigação e desenvolvimento, leva ao crescimento do mercado. Atualmente, estão a ser realizados vários estudos de investigação, que deverão criar uma vantagem competitiva para os fabricantes desenvolverem novos e inovadores tratamentos e terapias para a amaurose congénita de Leber, o que deverá proporcionar várias outras oportunidades no mercado da amaurose congénita de Leber. No entanto, espera-se que as rigorosas regulamentações governamentais sobre a aprovação e erros dos dispositivos durante a terapia de infusão dificultem o crescimento.
O relatório global do mercado de amaurose congénita fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, o impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado. A escalabilidade e expansão do negócio das unidades de retalho nos países em desenvolvimento de diversas regiões e a parceria com fornecedores para a distribuição segura de produtos de máquinas e medicamentos são os principais impulsionadores que impulsionaram a procura do mercado no período de previsão.
O mercado global de amaurose congénita leber é favorável e visa reduzir a progressão da doença. A Data Bridge Market Research analisa que o mercado global de amaurose congénita leve crescerá a um CAGR de 4,8% durante o período de previsão de 2022 a 2029.
|
Métrica de relatório |
Detalhes |
|
Período de previsão |
2022 a 2029 |
|
Ano base |
2021 |
|
Anos históricos |
2020 (personalizável para 2019 - 2014) |
|
Unidades Quantitativas |
Receita em milhões de dólares, preços em dólares |
|
Segmentos cobertos |
Por Tipo de Doença (Tipo Infantil, Tipo Juvenil e Outros), Tipo (Terapêutica, Diagnóstico), Utilizador Final (Hospitais, Clínicas Especializadas, Centros Cirúrgicos de Ambulatório , Assistência Médica Domiciliária e Outros), Canal de Distribuição (Concurso Directo e Venda a Retalho ) |
|
Países abrangidos |
Por país (EUA, Canadá, México, Alemanha, França, Itália, Reino Unido, Espanha, Países Baixos, Rússia, Suíça, Turquia, Áustria, Noruega, Hungria, Lituânia, Irlanda, Polónia, Resto da Europa, Japão, China, Índia, Sul Coreia, Austrália, Singapura, Malásia, Tailândia, Indonésia, Filipinas, Vietname, Resto da Ásia-Pacífico, Brasil, Argentina, Peru, Resto da América do Sul, Arábia Saudita, África do Sul, Emirados Árabes Unidos, Israel, Kuwait, Egito, Resto do Médio Oriente e África) |
|
Participantes do mercado abrangidos |
Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE NV, Optos, Metrovision, Blue Print Genetics Oy (uma subsidiária da Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio , Inc., Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. |
Dinâmica global do mercado de amaurose congénita de Leber
Motoristas
- Aumento da incidência e prevalência de mediado pelo gene rpe65 em doenças da retina
As distrofias retinianas hereditárias (IRDs) representam um grupo geneticamente diverso de doenças progressivas e visualmente debilitantes. Os doentes adultos e pediátricos com perda de visão devido a IRD causada por mutações bialélicas no gene do epitélio pigmentar da retina de 65 kDa (RPE65) são frequentemente diagnosticados clinicamente como retinite pigmentosa (RP) e amaurose congénita de Leber (LCA).
A amaurose congénita de Leber (LCA) é uma doença ocular que afeta principalmente a retina. A LCA é caracterizada por deficiência visual grave desde o nascimento ou nos primeiros meses de vida, movimentos oculares errantes ou nistagmo, respostas pupilares fracas à luz, sinal óculo digital (cutucar, esfregar e/ou pressionar os olhos) e sinais indetetáveis ou gravemente anormais. A LCA é geralmente herdada como uma condição genética autossómica recessiva.
- Aumento de produtos em pipeline e ensaios clínicos
A inovação contínua para o tratamento de doenças hereditárias da retina e da doença da amaurose congénita de Leber tem o potencial de ter um impacto positivo no mercado à medida que o tamanho do mercado aumentará, quando estes produtos forem aprovados no mercado global. Devido à ausência de tratamentos farmacológicos para a LCA, os principais players do mercado estão continuamente a inovar o tratamento ou a investir em I&D para o tratamento. Vários ensaios clínicos em curso estão a recrutar pessoas em todo o mundo para encontrar o mecanismo das doenças para o tratamento.
Oportunidades
- Aumento das iniciativas governamentais em relação à amaurose congénita de Leber
Segundo a OMS, a prevalência das IRD monogénicas afecta cerca de 1 em cada 40.000 recém-nascidos em todo o mundo. Para os evitar, os governos de vários países de todo o mundo tomaram iniciativas.
Os diversos programas e decisões tomadas pelos governos de todo o mundo para dar o melhor tratamento à sua população são o principal factor que deverá aumentar a procura e funcionarão como uma oportunidade para o mercado global da amaurose congénita leber.
Restrições/Desafios
O custo do produto desempenha um fator importante no mercado. No mercado das doenças hereditárias da retina, observa-se geralmente que o custo dos produtos é altamente sofisticado, precisa de ser preciso e outras especificações aumentam o custo do produto.
O elevado custo do tratamento deve-se aos vários pontos de controlo do tratamento juntamente com a utilização de modalidades de alta tecnologia para a realização de tais procedimentos de tratamento.
No entanto, os cuidados hospitalares aumentam ainda mais o custo da amaurose congénita de Leber. Uma vez que o custo dos produtos inovadores e avançados é elevado, o custo do tratamento aumenta proporcionalmente, devido ao qual se espera que o elevado custo associado ao tratamento e diagnóstico da amaurose congénita leber restrinja o crescimento global do mercado da amaurose congénita leber.
Considerando que a Agência Europeia do Medicamento não o faz. Os produtos de terapia genética são regulados pelo Centro de Avaliação e Investigação Biológica (CBER) da FDA. A FDA exige a apresentação de um IND antes de iniciar os estudos clínicos e um pedido de licença biológica aprovado (BLA) para comercializar o produto nos Estados Unidos. O quadro regulamentar para o desenvolvimento e fabrico de produtos de terapia genética compreende regulamentos e documentos de orientação, incluindo a interpretação destes documentos reguladores pelos reguladores.
No entanto, cada país é regido pelas diretrizes regulamentadas por diferentes autoridades que deverão atuar como um desafio ao crescimento do mercado global de amaurose congénita leber.
Desenvolvimentos recentes
- Em setembro de 2021, a Gyroscope Therapeutics Limited, empresa de terapia genética em fase clínica focada em doenças oculares, anunciou dados provisórios positivos do ensaio clínico aberto de Fase I/II em curso da sua terapia genética experimental única, GT005, em pessoas com atrofia geográfica (AG) secundária à degeneração macular relacionada com a idade (DMI).
- Em janeiro de 2020, a Allergan lançou o SkinMedica Instant Bright Eye Cream, um tratamento refrescante para os olhos que hidrata, ilumina e ajuda a refirmar visivelmente a aparência da delicada pele em redor dos olhos. O produto foi desenvolvido para melhorar imediatamente a aparência dos olhos e continuar a reduzir os sinais visíveis de envelhecimento e fadiga ao longo do tempo, incluindo olheiras, linhas finas e arrepios nas pálpebras superiores.
Segmentação global do mercado de amaurose congénita de Leber
O mercado global de amaurose congénita leber está categorizado em tipo de doença, tipo, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
Tipo de doença
- Tipo Infantil
- Tipo Juvenil
- Outros
Com base no tipo de doença, o mercado da amaurose congénita leber está segmentado em tipo infantil, tipo juvenil e outros
Tipo
- Diagnóstico
- Terapia
Com base no tipo, o mercado global de amaurose congénita leber está segmentado em diagnóstico e terapia. O segmento de diagnóstico é ainda segmentado em diagnóstico clínico e diagnóstico genético. O diagnóstico clínico é ainda segmentado em exame oftalmológico clínico, teste de campo visual, imagens de retalho e testes eletrofisiológicos. O diagnóstico clínico é subsegmentado em testes eletrofisiológicos, imagiologia da retina, teste de campo visual e exame oftalmológico clínico. Os testes de eletrofisiologia são subsegmentados em eletrorretinograma de campo total (ERG) e adaptometria escura (DA). A imagem da retina é subsegmentada em tomografia de coerência ótica (OCT), imagem de autofluorescência de fundo (FAF), oftalmoscopia de varrimento laser (SLO) e imagem de ótica adaptativa (AO) e imagem de fundo a cores convencional. Os testes de campo visual são subsegmentados em testes de campo visual computadorizados e testes de campo manuais. O exame clínico é subsegmentado em lâmpada de fenda, oftalmoscopia indireta, prova de refração e exame de dilatação. O segmento da terapia está ainda segmentado em terapia genética, terapia retinal, agentes neuroprotetores, entre outros. A terapia genética é ainda segmentada em luxturna e outros. Os agentes neuroprotetores são ainda segmentados em palmitato de vitamina A, ácido docosahexaenóico (DHA), luteína e outros.
Utilizador final
- Hospitais
- Clínicas especializadas
- Centros cirúrgicos de ambulatório
- Cuidados de saúde ao domicílio
- Outros
Com base no utilizador final, o mercado global de amaurose congénita leber está segmentado em hospitais, clínicas especializadas, centros de cirurgia ambulatória, cuidados de saúde domiciliários, entre outros.
Canal de distribuição
- Vendas no Retalho
- Concurso Direto
Com base no canal de distribuição, o mercado global de amaurose congénita leber está segmentado em vendas a retalho, concurso direto.
Análise/perspetivas regionais do mercado da amaurose congénita de Leber
O mercado da amaurose congénita leber é analisado e são fornecidos insights e tendências do tamanho do mercado por país, tipo de doença, tipo, utilizador final e canal de distribuição como mencionado acima.
Os países abrangidos no relatório de mercado Leber amaurose congénita são EUA, Canadá, México, Alemanha, França, Itália, Reino Unido, Espanha, Países Baixos, Rússia, Suíça, Turquia, Áustria, Noruega, Hungria, Lituânia, Irlanda, Polónia, Resto da Europa , Japão, China, Índia, Coreia do Sul, Austrália, Singapura, Malásia, Tailândia, Indonésia, Filipinas, Vietname, Resto da Ásia-Pacífico, Brasil, Argentina, Peru, Resto da América do Sul, Arábia Saudita, África do Sul , Emirados Árabes Unidos, Israel , Kuwait, Egito, Resto do Médio Oriente e África.
Espera-se que a Europa domine devido ao aumento do avanço tecnológico nas áreas em desenvolvimento.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.
Cenário competitivo e análise do mercado de amaurose congénita de Leber
O cenário competitivo do mercado global de amaurose congénita de Leber fornece detalhes pelos concorrentes. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, e domínio da aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas no mercado da amaurose congénita leber.
Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE NV, Optos, Metrovision, Blue Print Genetics Oy (uma subsidiária da Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio , Inc., Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co.
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Além disso, os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise da quota de mercado da empresa, padrões de medição, análise global versus regional e de participação dos fornecedores. Solicite a chamada do analista em caso de dúvidas adicionais.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL LEBER CONGENITAL AMAUROSIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PIPELINE ANALYSIS FOR GLOBAL LEBER CONGENTIAL AMAUROSIS MARKET
4.2 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS
4.3 PESTEL ANALYSIS
4.4 PORTERS FIVE FORCES
5 EPIDEMIOLOGY
6 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES
6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS
6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER
6.2 RESTRAINTS
6.2.1 LACK OF QUALIFIED PROFESSIONALS
6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE
6.3 OPPORTUNITIES
6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS
6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE
6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT
6.4 CHALLENGES
6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS
7 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.2 INFANTILE TYPE
7.3 JUVENILE TYPE
7.4 OTHERS
8 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE
8.1 OVERVIEW
8.2 THERAPY
8.2.1 GENE THERAPY
8.2.1.1 LUXTURNA
8.2.2 RETINAL PROSTHETIC
8.2.3 NEUROPROTECTIVE AGENTS
8.2.3.1 VITAMIN A PALMITATE
8.2.3.2 DOCOSAHEXAENOIC ACID
8.2.3.3 LUTEIN
8.2.3.4 OTHERS
8.2.4 OTHERS
8.3 DIAGNOSIS
8.3.1 CLINICAL DIAGNOSIS
8.3.1.1 ELECTROPHYSIOLOGICAL TESTS
8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG)
8.3.1.1.2 DARK ADAPTOMETRY (DA)
8.3.1.2 RETINAL IMAGING
8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)
8.3.1.2.2 FUNDUS AUTOFLUORESCENCE
8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO)
8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING
8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING
8.3.1.3 VISUAL FIELD TEST
8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS
8.3.1.3.2 MANUAL FIELD TEST
8.3.1.4 CLINICAL EYE EXAMINATION
8.3.1.4.1 SLIT LAMP
8.3.1.4.2 INDIRECT OPHTHALMOSCOPY
8.3.1.4.3 REFRACTION TEST
8.3.1.4.4 DILATION EXAM
8.3.1.5 OTHERS
8.3.2 GENETIC DIAGNOSIS
9 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALITY CLINICS
9.4 AMBULATORY SURGICAL CENTERS
9.5 HOME HEALTHCARE
9.6 OTHERS
10 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 RETAIL SALES
10.2.1.1 HOSPITAL PHARMACIES
10.2.1.2 RETAIL PHARMACIES
10.2.1.3 OTHERS
10.3 DIRECT TENDER
11 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.2.3 MEXICO
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 U.K.
11.3.4 RUSSIA
11.3.5 ITALY
11.3.6 SPAIN
11.3.7 NETHERLAND
11.3.8 SWITZERLAND
11.3.9 POLAND
11.3.10 TURKEY
11.3.11 AUSTRIA
11.3.12 HUNGARY
11.3.13 NORWAY
11.3.14 IRELAND
11.3.15 LITHUANIA
11.3.16 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 INDIA
11.4.4 SOUTH KOREA
11.4.5 AUSTRALIA
11.4.6 SINGAPORE
11.4.7 THAILAND
11.4.8 INDONESIA
11.4.9 PHILIPPINES
11.4.10 MALAYSIA
11.4.11 VIETNAM
11.4.12 REST OF ASIA-PACIFIC
11.5 SOUTH AMERICA
11.5.1 BRAZIL
11.5.2 ARGENTINA
11.5.3 PERU
11.5.4 REST OF SOUTH AMERICA
11.6 MIDDLE EAST AND AFRICA
11.6.1 SOUTH AFRICA
11.6.2 SAUDI ARABIA
11.6.3 U.A.E
11.6.4 ISRAEL
11.6.5 EGYPT
11.6.6 KUWAIT
11.6.7 REST OF MIDDLE EAST AND AFRICA
12 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 SPARK THERAPEUTICS, INC
14.1.1 COMPANY SNAPSHOT
14.1.2 COMPANY SHARE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.1.4.1 EU AUTHORIZATION
14.2 OPTOS
14.2.1 COMPANY SNAPSHOT
14.2.2 COMPANY SHARE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.2.4.1 PRODUCT APPROVAL
14.3 CD GENOMICS
14.3.1 COMPANY SNAPSHOT
14.3.2 COMPANY SHARE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.4.5.1 COLLABORATION
14.5 LKC TECHNOLOGIES, INC
14.5.1 COMPANY SNAPSHOT
14.5.2 COMPANY SHARE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.5.4.1 PRODUCT APPROVAL
14.5.5 PRODUCT APPROVAL
14.6 AGTC
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.6.4.1 AGREEMENT
14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 ASTELLAS PHARMA INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ATSENA THERAPEUTICS
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 CENTOGENE N.V.
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.10.4.1 PRODUCT LAUNCH
14.11 COAVE THERAPEUTICS
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 EDITAS MEDICINE
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENTS
14.12.4.1 DATA & TRAIL DATA PRESENTATION
14.13 ELUMINEX BIOSCIENCES
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 GYROSCOPE THERAPEUTICS LIMITED
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENTS
14.15 INVITAE CORPORATION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.15.4.1 NEW FACILITY
14.15.4.2 EXPANSION
14.16 IVERIC BIO.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 MEIRAGTX LIMITED
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 METROVISION
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.19.3.1 FDA CLEARANCE APPROVAL
14.2 OCUGEN INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 OKUVISION
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENTS
14.21.3.1 APPROVAL
14.22 PROQR THERAPEUTICS
14.22.1 COMPANY SNAPSHOT
14.22.2 PRODUCT PORTFOLIO
14.22.3 RECENT DEVELOPMENTS
14.23 REGENXBIO INC.
14.23.1 COMPANY SNAPSHOT
14.23.2 REVENUE ANALYSIS
14.23.3 PRODUCT PORTFOLIO
14.23.4 RECENT DEVELOPMENTS
14.24 SPARINGVISION
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tabela
TABLE 1 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 2 GLOBAL INFANTILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 GLOBAL JUVENILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 GLOBAL OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 GLOBAL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 GLOBAL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 GLOBAL GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 GLOBAL NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 GLOBAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 GLOBAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 GLOBAL CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 GLOBAL ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 GLOBAL RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 GLOBAL VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 GLOBAL CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 18 GLOBAL HOSPITALS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 GLOBAL SPECIALITY CLINICS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 GLOBAL AMBULATORY SURGICAL CENTERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 GLOBAL HOME HEALTHCARE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 GLOBAL OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 24 GLOBAL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 GLOBAL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 26 GLOBAL DIRECT TENDER IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 29 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 43 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 44 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 U.S. THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 46 U.S. GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 U.S. NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 U.S. DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 U.S. CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 U.S. RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 U.S. ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 U.S. VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 U.S. CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 56 U.S. RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 57 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 58 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 CANADA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 CANADA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 CANADA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 CANADA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 CANADA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 CANADA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 CANADA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 CANADA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 CANADA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 69 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 70 CANADA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 72 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 MEXICO THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 MEXICO GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 MEXICO NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 MEXICO DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 MEXICO CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 MEXICO RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 MEXICO ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 MEXICO VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 MEXICO CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 83 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 MEXICO RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 86 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 87 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 EUROPE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 EUROPE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 EUROPE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 EUROPE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 EUROPE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 EUROPE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 EUROPE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 EUROPE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 EUROPE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 98 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 99 EUROPE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 100 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 101 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 GERMANY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 GERMANY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 GERMANY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 GERMANY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 GERMANY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 GERMANY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 GERMANY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 GERMANY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 GERMANY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 112 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 113 GERMANY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 114 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 115 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 FRANCE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 117 FRANCE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 FRANCE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 FRANCE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 FRANCE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 FRANCE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 FRANCE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 123 FRANCE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 FRANCE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 126 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 127 FRANCE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 128 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 129 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 U.K. THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 U.K. GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 U.K. NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 U.K. DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 U.K. CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 135 U.K. RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 U.K. ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 137 U.K. VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 U.K. CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 141 U.K. RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 142 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 143 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 RUSSIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 RUSSIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 RUSSIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 RUSSIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 RUSSIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 149 RUSSIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 150 RUSSIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 RUSSIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 RUSSIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 154 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 155 RUSSIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 156 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 157 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 ITALY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 159 ITALY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 ITALY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 ITALY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 162 ITALY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 163 ITALY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 ITALY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 165 ITALY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 ITALY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 168 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 169 ITALY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 170 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 171 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 SPAIN THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 173 SPAIN GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 174 SPAIN NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 SPAIN DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 SPAIN CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 SPAIN RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 SPAIN ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 SPAIN VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 SPAIN CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 181 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 182 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 183 SPAIN RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 184 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 185 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 186 NETHERLAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 187 NETHERLAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 188 NETHERLAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 189 NETHERLAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 190 NETHERLAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 NETHERLAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 NETHERLAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 NETHERLAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 NETHERLAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 196 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 197 NETHERLAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 198 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 199 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 SWITZERLAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 201 SWITZERLAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 202 SWITZERLAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 203 SWITZERLAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 204 SWITZERLAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 205 SWITZERLAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 206 SWITZERLAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 SWITZERLAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 SWITZERLAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 209 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 210 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 211 SWITZERLAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 212 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 213 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 214 POLAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 215 POLAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 216 POLAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 217 POLAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 218 POLAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 219 POLAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 220 POLAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 POLAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 POLAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 224 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 225 POLAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 226 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 227 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 228 TURKEY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 229 TURKEY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 TURKEY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 231 TURKEY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 232 TURKEY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 233 TURKEY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 234 TURKEY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 235 TURKEY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 TURKEY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 238 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 239 TURKEY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 240 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 241 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 AUSTRIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 243 AUSTRIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 244 AUSTRIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 245 AUSTRIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 246 AUSTRIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 247 AUSTRIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 248 AUSTRIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 249 AUSTRIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 250 AUSTRIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 251 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 252 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 253 AUSTRIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 254 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 255 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 256 HUNGARY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 257 HUNGARY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 258 HUNGARY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 259 HUNGARY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 260 HUNGARY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 261 HUNGARY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 262 HUNGARY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 263 HUNGARY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 264 HUNGARY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 265 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 266 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 267 HUNGARY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 268 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 269 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 270 NORWAY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 271 NORWAY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 272 NORWAY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 273 NORWAY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 274 NORWAY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 275 NORWAY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 276 NORWAY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 277 NORWAY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 278 NORWAY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 279 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 280 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 281 NORWAY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 282 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 283 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 284 IRELAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 285 IRELAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 286 IRELAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 287 IRELAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 288 IRELAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 289 IRELAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 290 IRELAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 291 IRELAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 292 IRELAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 293 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 294 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 295 IRELAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 296 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 297 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 298 LITHUANIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 299 LITHUANIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 300 LITHUANIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 301 LITHUANIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 302 LITHUANIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 303 LITHUANIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 304 LITHUANIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 305 LITHUANIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 306 LITHUANIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 307 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 308 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 309 LITHUANIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 310 REST OF EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 311 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 312 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 313 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 314 ASIA-PACIFIC THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 315 ASIA-PACIFIC GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 316 ASIA-PACIFIC NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 317 ASIA-PACIFIC DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 318 ASIA-PACIFIC CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 319 ASIA-PACIFIC RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 320 ASIA-PACIFIC ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 321 ASIA-PACIFIC VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 322 ASIA-PACIFIC CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 323 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 324 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 325 ASIA-PACIFIC RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 326 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 327 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 328 CHINA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 329 CHINA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 330 CHINA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 331 CHINA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 332 CHINA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 333 CHINA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 334 CHINA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 335 CHINA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 336 CHINA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 337 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 338 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 339 CHINA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 340 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 341 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 342 JAPAN THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 343 JAPAN GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 344 JAPAN NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 345 JAPAN DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 346 JAPAN CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 347 JAPAN RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 348 JAPAN ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 349 JAPAN VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 350 JAPAN CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 351 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 352 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 353 JAPAN RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 354 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 355 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 356 INDIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 357 INDIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 358 INDIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 359 INDIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 360 INDIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 361 INDIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 362 INDIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 363 INDIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 364 INDIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 365 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 366 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 367 INDIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 368 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 369 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 370 SOUTH KOREA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 371 SOUTH KOREA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 372 SOUTH KOREA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 373 SOUTH KOREA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 374 SOUTH KOREA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 375 SOUTH KOREA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 376 SOUTH KOREA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 377 SOUTH KOREA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 378 SOUTH KOREA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 379 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 380 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 381 SOUTH KOREA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 382 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 383 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 384 AUSTRALIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 385 AUSTRALIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 386 AUSTRALIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 387 AUSTRALIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 388 AUSTRALIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 389 AUSTRALIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 390 AUSTRALIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 391 AUSTRALIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 392 AUSTRALIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 393 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 394 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 395 AUSTRALIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 396 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 397 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 398 SINGAPORE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 399 SINGAPORE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 400 SINGAPORE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 401 SINGAPORE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 402 SINGAPORE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 403 SINGAPORE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 404 SINGAPORE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 405 SINGAPORE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 406 SINGAPORE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 407 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 408 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 409 SINGAPORE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 410 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 411 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 412 THAILAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 413 THAILAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 414 THAILAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 415 THAILAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 416 THAILAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 417 THAILAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 418 THAILAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 419 THAILAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 420 THAILAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 421 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 422 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 423 THAILAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 424 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 425 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 426 INDONESIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 427 INDONESIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 428 INDONESIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 429 INDONESIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 430 INDONESIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 431 INDONESIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 432 INDONESIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 433 INDONESIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 434 INDONESIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 435 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 436 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 437 INDONESIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 438 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 439 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 440 PHILIPPINES THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 441 PHILIPPINES GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 442 PHILIPPINES NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 443 PHILIPPINES DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 444 PHILIPPINES CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 445 PHILIPPINES RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 446 PHILIPPINES ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 447 PHILIPPINES VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 448 PHILIPPINES CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 449 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 450 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 451 PHILIPPINES RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 452 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 453 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 454 MALAYSIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 455 MALAYSIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 456 MALAYSIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 457 MALAYSIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 458 MALAYSIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 459 MALAYSIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 460 MALAYSIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 461 MALAYSIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 462 MALAYSIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 463 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 464 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 465 MALAYSIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 466 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 467 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 468 VIETNAM THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 469 VIETNAM GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 470 VIETNAM NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 471 VIETNAM DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 472 VIETNAM CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 473 VIETNAM RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 474 VIETNAM ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 475 VIETNAM VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 476 VIETNAM CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 477 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 478 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 479 VIETNAM RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 480 REST OF ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 481 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 482 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 483 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 484 SOUTH AMERICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 485 SOUTH AMERICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 486 SOUTH AMERICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 487 SOUTH AMERICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 488 SOUTH AMERICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 489 SOUTH AMERICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 490 SOUTH AMERICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 491 SOUTH AMERICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 492 SOUTH AMERICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 493 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 494 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 495 SOUTH AMERICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 496 BRAZIL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 497 BRAZIL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 498 BRAZIL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 499 BRAZIL GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 500 BRAZIL NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 501 BRAZIL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 502 BRAZIL CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 503 BRAZIL RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 504 BRAZIL ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 505 BRAZIL VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 506 BRAZIL CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 507 BRAZIL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 508 BRAZIL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 509 BRAZIL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 510 ARGENTINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 511 ARGENTINA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 512 ARGENTINA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 513 ARGENTINA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 514 ARGENTINA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 515 ARGENTINA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 516 ARGENTINA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 517 ARGENTINA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 518 ARGENTINA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 519 ARGENTINA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 520 ARGENTINA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 521 ARGENTINA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 522 ARGENTINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 523 ARGENTINA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 524 PERU LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 525 PERU LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 526 PERU THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 527 PERU GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 528 PERU NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 529 PERU DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 530 PERU CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 531 PERU RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 532 PERU ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 533 PERU VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 534 PERU CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 535 PERU LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 536 PERU LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 537 PERU RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 538 REST OF SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 539 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 540 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 541 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 542 MIDDLE EAST AND AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 543 MIDDLE EAST AND AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 544 MIDDLE EAST AND AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 545 MIDDLE EAST AND AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 546 MIDDLE EAST AND AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 547 MIDDLE EAST AND AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 548 MIDDLE EAST AND AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 549 MIDDLE EAST AND AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 550 MIDDLE EAST AND AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 551 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 552 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 553 MIDDLE EAST AND AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 554 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 555 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 556 SOUTH AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 557 SOUTH AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 558 SOUTH AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 559 SOUTH AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 560 SOUTH AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 561 SOUTH AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 562 SOUTH AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 563 SOUTH AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 564 SOUTH AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 565 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 566 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 567 SOUTH AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 568 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 569 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 570 SAUDI ARABIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 571 SAUDI ARABIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 572 SAUDI ARABIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 573 SAUDI ARABIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 574 SAUDI ARABIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 575 SAUDI ARABIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 576 SAUDI ARABIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 577 SAUDI ARABIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 578 SAUDI ARABIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 579 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 580 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 581 SAUDI ARABIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 582 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 583 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 584 U.A.E THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 585 U.A.E GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 586 U.A.E NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 587 U.A.E DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 588 U.A.E CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 589 U.A.E RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 590 U.A.E ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 591 U.A.E VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 592 U.A.E CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 593 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 594 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 595 U.A.E RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 596 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 597 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 598 ISRAEL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 599 ISRAEL GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 600 ISRAEL NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 601 ISRAEL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 602 ISRAEL CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 603 ISRAEL RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 604 ISRAEL ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 605 ISRAEL VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 606 ISRAEL CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 607 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 608 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 609 ISRAEL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 610 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 611 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 612 EGYPT THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 613 EGYPT GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 614 EGYPT NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 615 EGYPT DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 616 EGYPT CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 617 EGYPT RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 618 EGYPT ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 619 EGYPT VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 620 EGYPT CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 621 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 622 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 623 EGYPT RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 624 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 625 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 626 KUWAIT THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 627 KUWAIT GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 628 KUWAIT NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 629 KUWAIT DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 630 KUWAIT CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 631 KUWAIT RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 632 KUWAIT ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 633 KUWAIT VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 634 KUWAIT CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 635 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 636 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 637 KUWAIT RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 638 REST OF MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
Lista de Figura
FIGURE 1 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION
FIGURE 2 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: END USER GRID
FIGURE 9 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION
FIGURE 11 RISING GOVERNMENT AWARENESS PROGRAMS ABOUT THE INHERITED RETINAL DISEASE IS EXPECTED TO DRIVE THE GLOBAL LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INFANTILE TYPE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL LEBER CONGENITAL AMAUROSIS MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET IN LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE GLOBAL LEBER CONGENITAL AMAUROSIS MARKET
FIGURE 16 PROPORTION OF RPE65 GENE MUTATION IN CLINICALLY DIAGNOSED LCA PATIENTS
FIGURE 17 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2021
FIGURE 18 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 19 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 20 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 21 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2021
FIGURE 22 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 23 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 24 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2021
FIGURE 26 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 27 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 28 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 30 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 31 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 32 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 33 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 34 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY REGION (2021)
FIGURE 35 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY REGION (2022 & 2029)
FIGURE 36 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY REGION (2021 & 2029)
FIGURE 37 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 38 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 39 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 40 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 43 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 44 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 45 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 48 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 49 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 50 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 51 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 52 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 53 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 54 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 55 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 56 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 57 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 58 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 59 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 60 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 61 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 62 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 63 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)
FIGURE 64 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)
FIGURE 65 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)
FIGURE 66 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
